Free Newsletter
FDA backs pediatric warnings on Zyprexa, Lamisil
In advance of tomorrow's pediatric advisory committee meeting at the FDA, agency staffers are recommending new cautionary language for Eli Lilly's antipsychotic Zyprexa (about the risks of weight gain and diabetes in children) and Novartis' antifungal Lamisil (about the risk of psychiatric side effects, also in children). Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment